- Home
- NTHI vs IMUX Comparison
NTHI vs IMUX Comparison
Compare NTHI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- IMUX
- Stock Information
- Founded
- NTHI 2008
- IMUX 2016
- Country
- NTHI United States
- IMUX United States
- Employees
- NTHI N/A
- IMUX N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- IMUX Health Care
- Exchange
- NTHI Nasdaq
- IMUX Nasdaq
- Market Cap
- NTHI 142.5M
- IMUX 107.3M
- IPO Year
- NTHI N/A
- IMUX N/A
- Fundamental
- Price
- NTHI $7.24
- IMUX $0.66
- Analyst Decision
- NTHI
- IMUX Strong Buy
- Analyst Count
- NTHI 0
- IMUX 6
- Target Price
- NTHI N/A
- IMUX $11.60
- AVG Volume (30 Days)
- NTHI 108.1K
- IMUX 1.4M
- Earning Date
- NTHI 01-01-0001
- IMUX 05-15-2025
- Dividend Yield
- NTHI N/A
- IMUX N/A
- EPS Growth
- NTHI N/A
- IMUX N/A
- EPS
- NTHI N/A
- IMUX N/A
- Revenue
- NTHI $79,990.00
- IMUX N/A
- Revenue This Year
- NTHI N/A
- IMUX N/A
- Revenue Next Year
- NTHI N/A
- IMUX N/A
- P/E Ratio
- NTHI N/A
- IMUX N/A
- Revenue Growth
- NTHI 13.52
- IMUX N/A
- 52 Week Low
- NTHI $4.11
- IMUX $0.56
- 52 Week High
- NTHI $25.00
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- IMUX 26.54
- Support Level
- NTHI N/A
- IMUX $0.56
- Resistance Level
- NTHI N/A
- IMUX $0.95
- Average True Range (ATR)
- NTHI 0.00
- IMUX 0.08
- MACD
- NTHI 0.00
- IMUX -0.03
- Stochastic Oscillator
- NTHI 0.00
- IMUX 20.22
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.